Capstone Therapeutics (CAPS) Misses Q1 EPS by 2c
Tweet
Share
E-mailGet Alerts CAPS Hot Sheet
Join SI Premium – FREE
Capstone Therapeutics (NASDAQ: CAPS) reported Q1 EPS of ($0.21), $0.02 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $12.6 million versus the consensus estimate of $10.5 million.
For earnings history and earnings-related data on Capstone Therapeutics (CAPS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Starts ICICI Prudential Asset Management (ICICIAMC:IN) at Overweight
- UBS Starts Compass Gas e Energia SA (PASS3:BZ) at Buy
- JPMorgan Starts BSE Limited (BSE:IN) at Neutral
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
